ID   ADRB2_HUMAN             Reviewed;         413 AA.
AC   P07550; B0LPE4; B2R7X2; O14823; O14824; O14825; O14826; Q4JG18; Q53GA6;
AC   Q6GMT4; Q6P4D8; Q8NEQ9; Q96EC3; Q9UCZ0; Q9UCZ1; Q9UCZ2; Q9UCZ3; Q9UH95;
AC   Q9UHA1; Q9UMZ5;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 3.
DT   07-APR-2021, entry version 236.
DE   RecName: Full=Beta-2 adrenergic receptor;
DE   AltName: Full=Beta-2 adrenoreceptor;
DE            Short=Beta-2 adrenoceptor;
GN   Name=ADRB2; Synonyms=ADRB2R, B2AR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT GLN-27.
RC   TISSUE=Brain;
RX   PubMed=3026848; DOI=10.1016/0014-5793(87)81436-9;
RA   Chung F.-Z., Lentes K.-U., Gocayne J.D., Fitzgerald M.G., Robinson D.A.,
RA   Kerlavage A.R., Fraser C.M., Venter J.C.;
RT   "Cloning and sequence analysis of the human brain beta-adrenergic receptor.
RT   Evolutionary relationship to rodent and avian beta-receptors and porcine
RT   muscarinic receptors.";
RL   FEBS Lett. 211:200-206(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-16 AND GLN-27.
RX   PubMed=3034889;
RA   Kobilka B.K., Frielle T., Dohlman H.G., Bolanowski M.A., Dixon R.A.F.,
RA   Keller P., Caron M.G., Lefkowitz R.J.;
RT   "Delineation of the intronless nature of the genes for the human and
RT   hamster beta 2-adrenergic receptor and their putative promoter regions.";
RL   J. Biol. Chem. 262:7321-7327(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-16 AND GLN-27.
RX   PubMed=3033609; DOI=10.1093/nar/15.8.3636;
RA   Schofield P.R., Rhee L.M., Peralta E.G.;
RT   "Primary structure of the human beta-adrenergic receptor gene.";
RL   Nucleic Acids Res. 15:3636-3636(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ARG-16 AND GLN-27.
RX   PubMed=3025863; DOI=10.1073/pnas.84.1.46;
RA   Kobilka B.K., Dixon R.A.F., Frielle T., Dohlman H.G., Bolanowski M.A.,
RA   Sigal I.S., Yang-Feng T.L., Francke U., Caron M.G., Lefkowitz R.J.;
RT   "cDNA for the human beta 2-adrenergic receptor: a protein with multiple
RT   membrane-spanning domains and encoded by a gene whose chromosomal location
RT   is shared with that of the receptor for platelet-derived growth factor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:46-50(1987).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLN-27.
RX   PubMed=2823249; DOI=10.1073/pnas.84.20.6995;
RA   Emorine L.J., Marullo S., Delavier-Klutchko C., Kaveri S.V.,
RA   Durieu-Trautmann O., Strosberg A.D.;
RT   "Structure of the gene for human beta 2-adrenergic receptor: expression and
RT   promoter characterization.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:6995-6999(1987).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-16; GLN-27; MET-34 AND
RP   ILE-164.
RX   PubMed=8383511; DOI=10.1165/ajrcmb/8.3.334;
RA   Reihsaus E., Innis M., Macintyre N., Liggett S.B.;
RT   "Mutations in the gene encoding for the beta 2-adrenergic receptor in
RT   normal and asthmatic subjects.";
RL   Am. J. Respir. Cell Mol. Biol. 8:334-339(1993).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLN-27; LEU-159; PHE-159
RP   AND ARG-375.
RC   TISSUE=Blood;
RX   PubMed=11246467; DOI=10.1017/s0003480000008009;
RA   Rupert J.L., Monsalve M.V., Devine D.V., Hochachka P.W.;
RT   "Beta2-adrenergic receptor allele frequencies in the Quechua, a high
RT   altitude native population.";
RL   Ann. Hum. Genet. 64:135-143(2000).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ARG-16 AND GLN-27.
RC   TISSUE=Heart;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT GLN-27.
RC   TISSUE=Thyroid;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLN-27 AND CYS-220.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLN-27.
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ARG-16 AND GLN-27.
RC   TISSUE=Fetal brain, Leukocyte, and Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [15]
RP   MUTAGENESIS OF ASP-79, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=2831218;
RA   Chung F.-Z., Wang C.-D., Potter P.C., Venter J.C., Fraser C.M.;
RT   "Site-directed mutagenesis and continuous expression of human beta-
RT   adrenergic receptors. Identification of a conserved aspartate residue
RT   involved in agonist binding and receptor activation.";
RL   J. Biol. Chem. 263:4052-4055(1988).
RN   [16]
RP   PALMITOYLATION AT CYS-341, AND MUTAGENESIS OF CYS-341.
RX   PubMed=2540197;
RA   O'Dowd B.F., Hnatowich M., Caron M.G., Lefkowitz R.J., Bouvier M.;
RT   "Palmitoylation of the human beta 2-adrenergic receptor. Mutation of Cys341
RT   in the carboxyl tail leads to an uncoupled nonpalmitoylated form of the
RT   receptor.";
RL   J. Biol. Chem. 264:7564-7569(1989).
RN   [17]
RP   MUTAGENESIS OF TYR-141; TYR-350; TYR-354 AND TYR-366, AND PHOSPHORYLATION
RP   AT TYR-141.
RX   PubMed=8521811; DOI=10.1002/j.1460-2075.1995.tb00241.x;
RA   Valiquette M., Parent S., Loisel T.P., Bouvier M.;
RT   "Mutation of tyrosine-141 inhibits insulin-promoted tyrosine
RT   phosphorylation and increased responsiveness of the human beta 2-adrenergic
RT   receptor.";
RL   EMBO J. 14:5542-5549(1995).
RN   [18]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=7822302; DOI=10.1074/jbc.270.2.720;
RA   Gurevich V.V., Dion S.B., Onorato J.J., Ptasienski J., Kim C.M.,
RA   Sterne-Marr R., Hosey M.M., Benovic J.L.;
RT   "Arrestin interactions with G protein-coupled receptors. Direct binding
RT   studies of wild type and mutant arrestins with rhodopsin, beta 2-
RT   adrenergic, and m2 muscarinic cholinergic receptors.";
RL   J. Biol. Chem. 270:720-731(1995).
RN   [19]
RP   INTERACTION WITH ARRB1.
RX   PubMed=9388255; DOI=10.1074/jbc.272.49.31051;
RA   Lin F.-T., Krueger K.M., Kendall H.E., Daaka Y., Fredericks Z.L.,
RA   Pitcher J.A., Lefkowitz R.J.;
RT   "Clathrin-mediated endocytosis of the beta-adrenergic receptor is regulated
RT   by phosphorylation/dephosphorylation of beta-arrestin1.";
RL   J. Biol. Chem. 272:31051-31057(1997).
RN   [20]
RP   INTERACTION WITH SLC9A3R1.
RX   PubMed=10499588; DOI=10.1038/45816;
RA   Cao T.T., Deacon H.W., Reczek D., Bretscher A., von Zastrow M.;
RT   "A kinase-regulated PDZ-domain interaction controls endocytic sorting of
RT   the beta2-adrenergic receptor.";
RL   Nature 401:286-290(1999).
RN   [21]
RP   INTERACTION WITH SRC AND ARRB1.
RX   PubMed=9924018; DOI=10.1126/science.283.5402.655;
RA   Luttrell L.M., Ferguson S.S.G., Daaka Y., Miller W.E., Maudsley S.,
RA   Della Rocca G.J., Lin F.-T., Kawakatsu H., Owada K., Luttrell D.K.,
RA   Caron M.G., Lefkowitz R.J.;
RT   "Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein
RT   kinase complexes.";
RL   Science 283:655-661(1999).
RN   [22]
RP   EFFECT OF PALMITOYLATION, PHOSPHORYLATION AT SER-345 AND SER-346, AND
RP   MUTAGENESIS OF 345-SER-SER-346.
RX   PubMed=11146000; DOI=10.1046/j.1471-4159.2001.00005.x;
RA   Moffett S., Rousseau G., Lagace M., Bouvier M.;
RT   "The palmitoylation state of the beta(2)-adrenergic receptor regulates the
RT   synergistic action of cyclic AMP-dependent protein kinase and beta-
RT   adrenergic receptor kinase involved in its phosphorylation and
RT   desensitization.";
RL   J. Neurochem. 76:269-279(2001).
RN   [23]
RP   INTERACTION WITH GPRASP1.
RX   PubMed=12142540; DOI=10.1126/science.1073308;
RA   Whistler J.L., Enquist J., Marley A., Fong J., Gladher F., Tsuruda P.,
RA   Murray S.R., Von Zastrow M.;
RT   "Modulation of postendocytic sorting of G protein-coupled receptors.";
RL   Science 297:615-620(2002).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-246, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [25]
RP   UBIQUITINATION, DEUBIQUITINATION BY USP20 AND USP33, AND INTERACTION WITH
RP   USP20 AND USP33.
RX   PubMed=19424180; DOI=10.1038/emboj.2009.128;
RA   Berthouze M., Venkataramanan V., Li Y., Shenoy S.K.;
RT   "The deubiquitinases USP33 and USP20 coordinate beta2 adrenergic receptor
RT   recycling and resensitization.";
RL   EMBO J. 28:1684-1696(2009).
RN   [26]
RP   INTERACTION WITH EGLN3 AND VHL, SUBCELLULAR LOCATION, INDUCTION,
RP   UBIQUITINATION, HYDROXYLATION AT PRO-382 AND PRO-395, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=19584355; DOI=10.1126/scisignal.2000444;
RA   Xie L., Xiao K., Whalen E.J., Forrester M.T., Freeman R.S., Fong G.,
RA   Gygi S.P., Lefkowitz R.J., Stamler J.S.;
RT   "Oxygen-regulated beta(2)-adrenergic receptor hydroxylation by EGLN3 and
RT   ubiquitylation by pVHL.";
RL   Sci. Signal. 2:RA33-RA33(2009).
RN   [27]
RP   UBIQUITINATION, SUBCELLULAR LOCATION, AND INTERACTION WITH ARRDC3.
RX   PubMed=20559325; DOI=10.1038/embor.2010.80;
RA   Nabhan J.F., Pan H., Lu Q.;
RT   "Arrestin domain-containing protein 3 recruits the NEDD4 E3 ligase to
RT   mediate ubiquitination of the beta2-adrenergic receptor.";
RL   EMBO Rep. 11:605-611(2010).
RN   [28]
RP   INTERACTION WITH SNX27.
RX   PubMed=20733053; DOI=10.1083/jcb.201004060;
RA   Lauffer B.E., Melero C., Temkin P., Lei C., Hong W., Kortemme T.,
RA   von Zastrow M.;
RT   "SNX27 mediates PDZ-directed sorting from endosomes to the plasma
RT   membrane.";
RL   J. Cell Biol. 190:565-574(2010).
RN   [29]
RP   INTERACTION WITH SNX27.
RX   PubMed=21602791; DOI=10.1038/ncb2252;
RA   Temkin P., Lauffer B., Jager S., Cimermancic P., Krogan N.J.,
RA   von Zastrow M.;
RT   "SNX27 mediates retromer tubule entry and endosome-to-plasma membrane
RT   trafficking of signalling receptors.";
RL   Nat. Cell Biol. 13:715-721(2011).
RN   [30]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH ARRDC3.
RX   PubMed=25220262; DOI=10.1002/pro.2549;
RA   Qi S., O'Hayre M., Gutkind J.S., Hurley J.H.;
RT   "Insights into beta2-adrenergic receptor binding from structures of the N-
RT   terminal lobe of ARRDC3.";
RL   Protein Sci. 23:1708-1716(2014).
RN   [31]
RP   INTERACTION WITH CNIH4.
RX   PubMed=24405750; DOI=10.1111/tra.12148;
RA   Sauvageau E., Rochdi M.D., Oueslati M., Hamdan F.F., Percherancier Y.,
RA   Simpson J.C., Pepperkok R., Bouvier M.;
RT   "CNIH4 interacts with newly synthesized GPCR and controls their export from
RT   the endoplasmic reticulum.";
RL   Traffic 15:383-400(2014).
RN   [32]
RP   SUBCELLULAR LOCATION, PALMITOYLATION AT CYS-265 AND CYS-341, AND
RP   MUTAGENESIS OF CYS-265 AND CYS-341.
RX   PubMed=27481942; DOI=10.1074/jbc.m116.725762;
RA   Adachi N., Hess D.T., McLaughlin P., Stamler J.S.;
RT   "S-Palmitoylation of a Novel Site in the beta2-Adrenergic Receptor
RT   Associated with a Novel Intracellular Itinerary.";
RL   J. Biol. Chem. 291:20232-20246(2016).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (3.4 ANGSTROMS) OF 1-365 IN COMPLEX WITH CARAZOLOL,
RP   AND TOPOLOGY.
RX   PubMed=17952055; DOI=10.1038/nature06325;
RA   Rasmussen S.G.F., Choi H.-J., Rosenbaum D.M., Kobilka T.S., Thian F.S.,
RA   Edwards P.C., Burghammer M., Ratnala V.R.P., Sanishvili R., Fischetti R.F.,
RA   Schertler G.F.X., Weis W.I., Kobilka B.K.;
RT   "Crystal structure of the human beta2 adrenergic G-protein-coupled
RT   receptor.";
RL   Nature 450:383-387(2007).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 1-365 IN COMPLEX WITH CARAZOLOL
RP   AND CHOLESTEROL, DISULFIDE BONDS, TOPOLOGY, AND PALMITOYLATION AT CYS-341.
RX   PubMed=17962520; DOI=10.1126/science.1150577;
RA   Cherezov V., Rosenbaum D.M., Hanson M.A., Rasmussen S.G.F., Thian F.S.,
RA   Kobilka T.S., Choi H.-J., Kuhn P., Weis W.I., Kobilka B.K., Stevens R.C.;
RT   "High-resolution crystal structure of an engineered human beta2-adrenergic
RT   G protein-coupled receptor.";
RL   Science 318:1258-1265(2007).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 1-365 IN COMPLEX WITH TIMOLOL AND
RP   CHOLESTEROL, DISULFIDE BONDS, TOPOLOGY, AND PALMITOYLATION AT CYS-341.
RX   PubMed=18547522; DOI=10.1016/j.str.2008.05.001;
RA   Hanson M.A., Cherezov V., Griffith M.T., Roth C.B., Jaakola V.P.,
RA   Chien E.Y., Velasquez J., Kuhn P., Stevens R.C.;
RT   "A specific cholesterol binding site is established by the 2.8 A structure
RT   of the human beta2-adrenergic receptor.";
RL   Structure 16:897-905(2008).
RN   [36]
RP   VARIANTS ARG-16 AND GLN-27, CHARACTERIZATION, FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=7915137; DOI=10.1021/bi00198a006;
RA   Green S.A., Turki J., Innis M., Ligget S.B.;
RT   "Amino-terminal polymorphisms of the human beta 2-adrenergic receptor
RT   impart distinct agonist-promoted regulatory properties.";
RL   Biochemistry 33:9414-9419(1994).
RN   [37]
RP   VARIANT ARG-16, AND POLYMORPHISM.
RX   PubMed=7706471; DOI=10.1172/jci117838;
RA   Turki J., Pak J., Green S.A., Martin R.J., Liggett S.B.;
RT   "Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and
RT   nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal
RT   phenotype.";
RL   J. Clin. Invest. 95:1635-1641(1995).
CC   -!- FUNCTION: Beta-adrenergic receptors mediate the catecholamine-induced
CC       activation of adenylate cyclase through the action of G proteins. The
CC       beta-2-adrenergic receptor binds epinephrine with an approximately 30-
CC       fold greater affinity than it does norepinephrine.
CC       {ECO:0000269|PubMed:2831218, ECO:0000269|PubMed:7915137}.
CC   -!- SUBUNIT: Binds SLC9A3R1 and GPRASP1. Interacts with ARRB1 and ARRB2.
CC       Interacts with SRC, USP20 and USP33. Interacts with VHL; the
CC       interaction, which is increased on hydroxylation of ADRB2,
CC       ubiquitinates ADRB2 leading to its degradation. Interacts with EGLN3;
CC       the interaction hydroxylates ADRB2 facilitating VHL-E3 ligase-mediated
CC       ubiquitination. Interacts (via PDZ-binding motif) with SNX27 (via PDZ
CC       domain); the interaction is required when endocytosed to prevent
CC       degradation in lysosomes and promote recycling to the plasma membrane.
CC       Interacts with CNIH4 (PubMed:24405750). Interacts with ARRDC3
CC       (PubMed:20559325, PubMed:25220262). {ECO:0000269|PubMed:10499588,
CC       ECO:0000269|PubMed:12142540, ECO:0000269|PubMed:17952055,
CC       ECO:0000269|PubMed:17962520, ECO:0000269|PubMed:18547522,
CC       ECO:0000269|PubMed:19424180, ECO:0000269|PubMed:19584355,
CC       ECO:0000269|PubMed:20559325, ECO:0000269|PubMed:20733053,
CC       ECO:0000269|PubMed:21602791, ECO:0000269|PubMed:24405750,
CC       ECO:0000269|PubMed:25220262, ECO:0000269|PubMed:7822302,
CC       ECO:0000269|PubMed:9388255, ECO:0000269|PubMed:9924018}.
CC   -!- INTERACTION:
CC       P07550; P30542: ADORA1; NbExp=5; IntAct=EBI-491169, EBI-2903663;
CC       P07550; P07550: ADRB2; NbExp=4; IntAct=EBI-491169, EBI-491169;
CC       P07550; P32121: ARRB2; NbExp=3; IntAct=EBI-491169, EBI-714559;
CC       P07550; Q96B67: ARRDC3; NbExp=6; IntAct=EBI-491169, EBI-2875665;
CC       P07550; Q9UII2: ATP5IF1; NbExp=3; IntAct=EBI-491169, EBI-718459;
CC       P07550; Q9ULD4-2: BRPF3; NbExp=3; IntAct=EBI-491169, EBI-23662416;
CC       P07550; Q9NSI6-4: BRWD1; NbExp=3; IntAct=EBI-491169, EBI-10693038;
CC       P07550; Q5M9N0-2: CCDC158; NbExp=3; IntAct=EBI-491169, EBI-21796846;
CC       P07550; A0AVK6: E2F8; NbExp=3; IntAct=EBI-491169, EBI-7779316;
CC       P07550; Q658K8: EEF1DP3; NbExp=3; IntAct=EBI-491169, EBI-10248874;
CC       P07550; O00472: ELL2; NbExp=3; IntAct=EBI-491169, EBI-395274;
CC       P07550; Q15910-2: EZH2; NbExp=3; IntAct=EBI-491169, EBI-10699473;
CC       P07550; Q15486: GUSBP1; NbExp=3; IntAct=EBI-491169, EBI-712457;
CC       P07550; P61978: HNRNPK; NbExp=2; IntAct=EBI-491169, EBI-304185;
CC       P07550; Q5TCQ9: MAGI3; NbExp=9; IntAct=EBI-491169, EBI-310506;
CC       P07550; Q99685: MGLL; NbExp=2; IntAct=EBI-491169, EBI-721306;
CC       P07550; Q9NR21-5: PARP11; NbExp=3; IntAct=EBI-491169, EBI-17159452;
CC       P07550; Q8WVD3: RNF138; NbExp=3; IntAct=EBI-491169, EBI-749039;
CC       P07550; Q9H0X6: RNF208; NbExp=3; IntAct=EBI-491169, EBI-751555;
CC       P07550; O14745: SLC9A3R1; NbExp=6; IntAct=EBI-491169, EBI-349787;
CC       P07550; Q13573: SNW1; NbExp=3; IntAct=EBI-491169, EBI-632715;
CC       P07550; P12931: SRC; NbExp=3; IntAct=EBI-491169, EBI-621482;
CC       P07550; Q5T0J7-2: TEX35; NbExp=3; IntAct=EBI-491169, EBI-12833746;
CC       P07550; Q8N0U2: TMEM61; NbExp=3; IntAct=EBI-491169, EBI-25830583;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19584355,
CC       ECO:0000269|PubMed:20559325, ECO:0000269|PubMed:25220262,
CC       ECO:0000269|PubMed:2831218, ECO:0000269|PubMed:7915137}; Multi-pass
CC       membrane protein {ECO:0000269|PubMed:19584355}. Early endosome
CC       {ECO:0000269|PubMed:20559325}. Golgi apparatus
CC       {ECO:0000269|PubMed:27481942}. Note=Colocalizes with VHL at the cell
CC       membrane (PubMed:19584355). Activated receptors are internalized into
CC       endosomes prior to their degradation in lysosomes (PubMed:20559325).
CC       Activated receptors are also detected within the Golgi apparatus
CC       (PubMed:27481942). {ECO:0000269|PubMed:19584355,
CC       ECO:0000269|PubMed:20559325, ECO:0000269|PubMed:27481942}.
CC   -!- PTM: Palmitoylated (PubMed:2540197, PubMed:11146000, PubMed:27481942,
CC       PubMed:17962520, PubMed:18547522). Mainly palmitoylated at Cys-341
CC       (PubMed:2540197, PubMed:17962520, PubMed:18547522). Palmitoylation may
CC       reduce accessibility of phosphorylation sites by anchoring the receptor
CC       to the plasma membrane. Agonist stimulation promotes depalmitoylation
CC       and further allows Ser-345 and Ser-346 phosphorylation
CC       (PubMed:11146000). Also undergoes transient, ligand-induced
CC       palmitoylation at Cys-265 probably by ZDHHC9, ZDHHC14 and ZDHHC18
CC       within the Golgi (PubMed:27481942). Palmitoylation at Cys-265 requires
CC       phosphorylation by PKA and receptor internalization and stabilizes the
CC       receptor (PubMed:27481942). Could be depalmitoylated by LYPLA1 at the
CC       plasma membrane (PubMed:27481942). {ECO:0000269|PubMed:11146000,
CC       ECO:0000269|PubMed:17962520, ECO:0000269|PubMed:18547522,
CC       ECO:0000269|PubMed:2540197, ECO:0000269|PubMed:27481942}.
CC   -!- PTM: Phosphorylated by PKA and BARK upon agonist stimulation, which
CC       mediates homologous desensitization of the receptor. PKA-mediated
CC       phosphorylation seems to facilitate phosphorylation by BARK.
CC   -!- PTM: Phosphorylation of Tyr-141 is induced by insulin and leads to
CC       supersensitization of the receptor. {ECO:0000269|PubMed:8521811}.
CC   -!- PTM: Polyubiquitinated. Agonist-induced ubiquitination leads to sort
CC       internalized receptors to the lysosomes for degradation
CC       (PubMed:19424180, PubMed:20559325). Deubiquitination by USP20 and
CC       USP33, leads to ADRB2 recycling and resensitization after prolonged
CC       agonist stimulation. USP20 and USP33 are constitutively associated and
CC       are dissociated immediately after agonist stimulation. Ubiquitination
CC       by the VHL-E3 ligase complex is oxygen-dependent.
CC       {ECO:0000269|PubMed:19424180, ECO:0000269|PubMed:20559325}.
CC   -!- PTM: Hydroxylation by EGLN3 occurs only under normoxia and increases
CC       the interaction with VHL and the subsequent ubiquitination and
CC       degradation of ADRB2. {ECO:0000269|PubMed:19424180,
CC       ECO:0000269|PubMed:19584355}.
CC   -!- POLYMORPHISM: The Gly-16 allele is overrepresented in individuals
CC       affected by nocturnal asthma as compared to controls, and appears to be
CC       an important genetic factor in the expression of this asthmatic
CC       phenotype.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       Adrenergic receptor subfamily. ADRB2 sub-subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD96745.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/adrb2/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X04827; CAA28511.1; -; mRNA.
DR   EMBL; Y00106; CAA68289.1; -; Genomic_DNA.
DR   EMBL; M15169; AAA88015.1; -; mRNA.
DR   EMBL; J02960; AAA88017.1; -; Genomic_DNA.
DR   EMBL; AF022953; AAB82148.1; -; Genomic_DNA.
DR   EMBL; AF022954; AAB82149.1; -; Genomic_DNA.
DR   EMBL; AF022955; AAB82150.1; -; Genomic_DNA.
DR   EMBL; AF022956; AAB82151.1; -; Genomic_DNA.
DR   EMBL; AF169225; AAD48036.1; -; Genomic_DNA.
DR   EMBL; AF202305; AAF17569.1; -; Genomic_DNA.
DR   EMBL; AF203386; AAF20199.1; -; Genomic_DNA.
DR   EMBL; AY136741; AAN01267.1; -; mRNA.
DR   EMBL; AK313151; BAG35969.1; -; mRNA.
DR   EMBL; AK223025; BAD96745.1; ALT_INIT; mRNA.
DR   EMBL; DQ094845; AAY88739.1; -; Genomic_DNA.
DR   EMBL; EU332834; ABY87523.1; -; Genomic_DNA.
DR   EMBL; CH471062; EAW61798.1; -; Genomic_DNA.
DR   EMBL; BC012481; AAH12481.3; -; mRNA.
DR   EMBL; BC063486; AAH63486.2; -; mRNA.
DR   EMBL; BC073856; AAH73856.1; -; mRNA.
DR   CCDS; CCDS4292.1; -.
DR   PIR; A27525; QRHUB2.
DR   RefSeq; NP_000015.1; NM_000024.5.
DR   PDB; 1GQ4; X-ray; 1.90 A; A=409-413.
DR   PDB; 2R4R; X-ray; 3.40 A; A=1-365.
DR   PDB; 2R4S; X-ray; 3.40 A; A=24-365.
DR   PDB; 2RH1; X-ray; 2.40 A; A=1-230, A=263-365.
DR   PDB; 3D4S; X-ray; 2.80 A; A=1-230, A=263-348.
DR   PDB; 3KJ6; X-ray; 3.40 A; A=2-365.
DR   PDB; 3NY8; X-ray; 2.84 A; A=1-230, A=263-348.
DR   PDB; 3NY9; X-ray; 2.84 A; A=1-230, A=263-348.
DR   PDB; 3NYA; X-ray; 3.16 A; A=1-230, A=263-348.
DR   PDB; 3P0G; X-ray; 3.50 A; A=1-230, A=263-365.
DR   PDB; 3PDS; X-ray; 3.50 A; A=25-230, A=264-348.
DR   PDB; 3SN6; X-ray; 3.20 A; R=29-365.
DR   PDB; 4GBR; X-ray; 3.99 A; A=29-365.
DR   PDB; 4LDE; X-ray; 2.79 A; A=29-348.
DR   PDB; 4LDL; X-ray; 3.10 A; A=29-348.
DR   PDB; 4LDO; X-ray; 3.20 A; A=29-348.
DR   PDB; 4QKX; X-ray; 3.30 A; A=29-348.
DR   PDB; 5D5A; X-ray; 2.48 A; A=1-230, A=263-365.
DR   PDB; 5D5B; X-ray; 3.80 A; A=1-230, A=263-365.
DR   PDB; 5D6L; X-ray; 3.20 A; A=1-223, A=264-365.
DR   PDB; 5JQH; X-ray; 3.20 A; A/B=30-348.
DR   PDB; 5X7D; X-ray; 2.70 A; A=1-230, A=264-365.
DR   PDB; 6E67; X-ray; 3.70 A; A/B=1-232, A/B=268-365.
DR   PDB; 6KR8; NMR; -; A=25-350.
DR   PDB; 6MXT; X-ray; 2.96 A; A=29-365.
DR   PDB; 6N48; X-ray; 3.20 A; A=29-348.
DR   PDB; 6NI3; EM; 3.80 A; R=29-341.
DR   PDB; 6OBA; X-ray; 3.10 A; A=1-230, A=264-365.
DR   PDB; 6PRZ; X-ray; 2.80 A; A=1-230, A=264-348.
DR   PDB; 6PS0; X-ray; 3.40 A; A=1-230, A=264-348.
DR   PDB; 6PS1; X-ray; 3.20 A; A=1-230, A=264-348.
DR   PDB; 6PS2; X-ray; 2.40 A; A=1-230, A=264-348.
DR   PDB; 6PS3; X-ray; 2.50 A; A=1-230, A=264-348.
DR   PDB; 6PS4; X-ray; 2.60 A; A=1-230, A=264-348.
DR   PDB; 6PS5; X-ray; 2.90 A; A=1-230, A=264-348.
DR   PDB; 6PS6; X-ray; 2.70 A; A=1-230, A=264-348.
DR   PDB; 7BZ2; EM; 3.82 A; R=1-348.
DR   PDB; 7DHI; EM; 3.26 A; R=1-348.
DR   PDB; 7DHR; EM; 3.80 A; R=1-348.
DR   PDBsum; 1GQ4; -.
DR   PDBsum; 2R4R; -.
DR   PDBsum; 2R4S; -.
DR   PDBsum; 2RH1; -.
DR   PDBsum; 3D4S; -.
DR   PDBsum; 3KJ6; -.
DR   PDBsum; 3NY8; -.
DR   PDBsum; 3NY9; -.
DR   PDBsum; 3NYA; -.
DR   PDBsum; 3P0G; -.
DR   PDBsum; 3PDS; -.
DR   PDBsum; 3SN6; -.
DR   PDBsum; 4GBR; -.
DR   PDBsum; 4LDE; -.
DR   PDBsum; 4LDL; -.
DR   PDBsum; 4LDO; -.
DR   PDBsum; 4QKX; -.
DR   PDBsum; 5D5A; -.
DR   PDBsum; 5D5B; -.
DR   PDBsum; 5D6L; -.
DR   PDBsum; 5JQH; -.
DR   PDBsum; 5X7D; -.
DR   PDBsum; 6E67; -.
DR   PDBsum; 6KR8; -.
DR   PDBsum; 6MXT; -.
DR   PDBsum; 6N48; -.
DR   PDBsum; 6NI3; -.
DR   PDBsum; 6OBA; -.
DR   PDBsum; 6PRZ; -.
DR   PDBsum; 6PS0; -.
DR   PDBsum; 6PS1; -.
DR   PDBsum; 6PS2; -.
DR   PDBsum; 6PS3; -.
DR   PDBsum; 6PS4; -.
DR   PDBsum; 6PS5; -.
DR   PDBsum; 6PS6; -.
DR   PDBsum; 7BZ2; -.
DR   PDBsum; 7DHI; -.
DR   PDBsum; 7DHR; -.
DR   SMR; P07550; -.
DR   BioGRID; 106663; 314.
DR   CORUM; P07550; -.
DR   DIP; DIP-33948N; -.
DR   ELM; P07550; -.
DR   IntAct; P07550; 107.
DR   MINT; P07550; -.
DR   STRING; 9606.ENSP00000305372; -.
DR   BindingDB; P07550; -.
DR   ChEMBL; CHEMBL210; -.
DR   DrugBank; DB07543; (S)-carazolol.
DR   DrugBank; DB01193; Acebutolol.
DR   DrugBank; DB00866; Alprenolol.
DR   DrugBank; DB01118; Amiodarone.
DR   DrugBank; DB00182; Amphetamine.
DR   DrugBank; DB01102; Arbutamine.
DR   DrugBank; DB01274; Arformoterol.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB09204; Arotinolol.
DR   DrugBank; DB06216; Asenapine.
DR   DrugBank; DB00335; Atenolol.
DR   DrugBank; DB01408; Bambuterol.
DR   DrugBank; DB05590; Bedoradrine.
DR   DrugBank; DB09013; Befunolol.
DR   DrugBank; DB00195; Betaxolol.
DR   DrugBank; DB00217; Bethanidine.
DR   DrugBank; DB01295; Bevantolol.
DR   DrugBank; DB00612; Bisoprolol.
DR   DrugBank; DB00901; Bitolterol.
DR   DrugBank; DB08807; Bopindolol.
DR   DrugBank; DB06726; Bufuralol.
DR   DrugBank; DB08808; Bupranolol.
DR   DrugBank; DB00248; Cabergoline.
DR   DrugBank; DB00521; Carteolol.
DR   DrugBank; DB01136; Carvedilol.
DR   DrugBank; DB04846; Celiprolol.
DR   DrugBank; DB01407; Clenbuterol.
DR   DrugBank; DB00785; Cryptenamine.
DR   DrugBank; DB01151; Desipramine.
DR   DrugBank; DB11273; Dihydroergocornine.
DR   DrugBank; DB13345; Dihydroergocristine.
DR   DrugBank; DB00449; Dipivefrin.
DR   DrugBank; DB11278; DL-Methylephedrine.
DR   DrugBank; DB00841; Dobutamine.
DR   DrugBank; DB09273; Doxofylline.
DR   DrugBank; DB06262; Droxidopa.
DR   DrugBank; DB01363; Ephedra sinica root.
DR   DrugBank; DB01364; Ephedrine.
DR   DrugBank; DB00668; Epinephrine.
DR   DrugBank; DB01049; Ergoloid mesylate.
DR   DrugBank; DB11587; Etafedrine.
DR   DrugBank; DB01288; Fenoterol.
DR   DrugBank; DB00983; Formoterol.
DR   DrugBank; DB05039; Indacaterol.
DR   DrugBank; DB00221; Isoetharine.
DR   DrugBank; DB01064; Isoprenaline.
DR   DrugBank; DB00598; Labetalol.
DR   DrugBank; DB01210; Levobunolol.
DR   DrugBank; DB13139; Levosalbutamol.
DR   DrugBank; DB01365; Mephentermine.
DR   DrugBank; DB01214; Metipranolol.
DR   DrugBank; DB00264; Metoprolol.
DR   DrugBank; DB01203; Nadolol.
DR   DrugBank; DB05849; NCX 950.
DR   DrugBank; DB04861; Nebivolol.
DR   DrugBank; DB00368; Norepinephrine.
DR   DrugBank; DB00540; Nortriptyline.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB09080; Olodaterol.
DR   DrugBank; DB00816; Orciprenaline.
DR   DrugBank; DB01580; Oxprenolol.
DR   DrugBank; DB00715; Paroxetine.
DR   DrugBank; DB01359; Penbutolol.
DR   DrugBank; DB00925; Phenoxybenzamine.
DR   DrugBank; DB00397; Phenylpropanolamine.
DR   DrugBank; DB00960; Pindolol.
DR   DrugBank; DB01291; Pirbuterol.
DR   DrugBank; DB01366; Procaterol.
DR   DrugBank; DB01182; Propafenone.
DR   DrugBank; DB00571; Propranolol.
DR   DrugBank; DB06814; Protokylol.
DR   DrugBank; DB00852; Pseudoephedrine.
DR   DrugBank; DB01917; Putrescine.
DR   DrugBank; DB11124; Racepinephrine.
DR   DrugBank; DB00867; Ritodrine.
DR   DrugBank; DB01001; Salbutamol.
DR   DrugBank; DB00938; Salmeterol.
DR   DrugBank; DB00489; Sotalol.
DR   DrugBank; DB03566; Spermidine.
DR   DrugBank; DB00127; Spermine.
DR   DrugBank; DB00871; Terbutaline.
DR   DrugBank; DB00373; Timolol.
DR   DrugBank; DB00726; Trimipramine.
DR   DrugBank; DB12248; Tulobuterol.
DR   DrugBank; DB09082; Vilanterol.
DR   DrugCentral; P07550; -.
DR   GuidetoPHARMACOLOGY; 29; -.
DR   MoonDB; P07550; Predicted.
DR   TCDB; 9.A.14.3.5; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P07550; 2 sites.
DR   iPTMnet; P07550; -.
DR   PhosphoSitePlus; P07550; -.
DR   SwissPalm; P07550; -.
DR   BioMuta; ADRB2; -.
DR   DMDM; 296439450; -.
DR   EPD; P07550; -.
DR   jPOST; P07550; -.
DR   MassIVE; P07550; -.
DR   PaxDb; P07550; -.
DR   PeptideAtlas; P07550; -.
DR   PRIDE; P07550; -.
DR   ProteomicsDB; 52013; -.
DR   ABCD; P07550; 18 sequenced antibodies.
DR   Antibodypedia; 15959; 1107 antibodies.
DR   DNASU; 154; -.
DR   Ensembl; ENST00000305988; ENSP00000305372; ENSG00000169252.
DR   GeneID; 154; -.
DR   KEGG; hsa:154; -.
DR   CTD; 154; -.
DR   DisGeNET; 154; -.
DR   GeneCards; ADRB2; -.
DR   HGNC; HGNC:286; ADRB2.
DR   HPA; ENSG00000169252; Tissue enhanced (blood).
DR   MalaCards; ADRB2; -.
DR   MIM; 109690; gene+phenotype.
DR   neXtProt; NX_P07550; -.
DR   OpenTargets; ENSG00000169252; -.
DR   PharmGKB; PA39; -.
DR   VEuPathDB; HostDB:ENSG00000169252.5; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00940000159538; -.
DR   HOGENOM; CLU_009579_11_0_1; -.
DR   InParanoid; P07550; -.
DR   OMA; CLREHKA; -.
DR   OrthoDB; 614199at2759; -.
DR   PhylomeDB; P07550; -.
DR   TreeFam; TF316350; -.
DR   PathwayCommons; P07550; -.
DR   Reactome; R-HSA-390696; Adrenoceptors.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   SignaLink; P07550; -.
DR   SIGNOR; P07550; -.
DR   BioGRID-ORCS; 154; 6 hits in 992 CRISPR screens.
DR   ChiTaRS; ADRB2; human.
DR   EvolutionaryTrace; P07550; -.
DR   GeneWiki; Beta-2_adrenergic_receptor; -.
DR   GenomeRNAi; 154; -.
DR   Pharos; P07550; Tclin.
DR   PRO; PR:P07550; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; P07550; protein.
DR   Bgee; ENSG00000169252; Expressed in squamous epithelium and 197 other tissues.
DR   ExpressionAtlas; P07550; baseline and differential.
DR   Genevisible; P07550; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005769; C:early endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005768; C:endosome; TAS:ProtInc.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005764; C:lysosome; TAS:ProtInc.
DR   GO; GO:0016020; C:membrane; NAS:ARUK-UCL.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:HGNC-UCL.
DR   GO; GO:0008179; F:adenylate cyclase binding; IEA:Ensembl.
DR   GO; GO:0001540; F:amyloid-beta binding; IDA:ARUK-UCL.
DR   GO; GO:0004941; F:beta2-adrenergic receptor activity; IDA:HGNC-UCL.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0051380; F:norepinephrine binding; IDA:HGNC-UCL.
DR   GO; GO:0015459; F:potassium channel regulator activity; IDA:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:HGNC-UCL.
DR   GO; GO:0044877; F:protein-containing complex binding; IPI:ARUK-UCL.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; IDA:HGNC-UCL.
DR   GO; GO:0007171; P:activation of transmembrane receptor protein tyrosine kinase activity; TAS:ProtInc.
DR   GO; GO:0071880; P:adenylate cyclase-activating adrenergic receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0071875; P:adrenergic receptor signaling pathway; IDA:CAFA.
DR   GO; GO:0045453; P:bone resorption; IEA:Ensembl.
DR   GO; GO:0050873; P:brown fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:1904646; P:cellular response to amyloid-beta; IGI:ARUK-UCL.
DR   GO; GO:0002032; P:desensitization of G protein-coupled receptor signaling pathway by arrestin; IDA:HGNC-UCL.
DR   GO; GO:0002024; P:diet induced thermogenesis; IEA:Ensembl.
DR   GO; GO:0008333; P:endosome to lysosome transport; TAS:ProtInc.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0031649; P:heat generation; IEA:Ensembl.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0002862; P:negative regulation of inflammatory response to antigenic stimulus; TAS:Reactome.
DR   GO; GO:0040015; P:negative regulation of multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0045986; P:negative regulation of smooth muscle contraction; IBA:GO_Central.
DR   GO; GO:0002025; P:norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure; IBA:GO_Central.
DR   GO; GO:2000969; P:positive regulation of AMPA receptor activity; IGI:ARUK-UCL.
DR   GO; GO:1901098; P:positive regulation of autophagosome maturation; IDA:GO_Central.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; IEA:Ensembl.
DR   GO; GO:2000481; P:positive regulation of cAMP-dependent protein kinase activity; TAS:ARUK-UCL.
DR   GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; ISS:YuBioLab.
DR   GO; GO:1904504; P:positive regulation of lipophagy; IDA:GO_Central.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:HGNC-UCL.
DR   GO; GO:0061885; P:positive regulation of mini excitatory postsynaptic potential; IEA:Ensembl.
DR   GO; GO:0010739; P:positive regulation of protein kinase A signaling; IGI:ARUK-UCL.
DR   GO; GO:0071902; P:positive regulation of protein serine/threonine kinase activity; IGI:ARUK-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; IDA:HGNC-UCL.
DR   GO; GO:0002028; P:regulation of sodium ion transport; IEA:Ensembl.
DR   GO; GO:0009409; P:response to cold; IEA:Ensembl.
DR   GO; GO:1990911; P:response to psychosocial stress; TAS:ARUK-UCL.
DR   InterPro; IPR002233; ADR_fam.
DR   InterPro; IPR000332; ADRB2_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   PANTHER; PTHR24248:SF21; PTHR24248:SF21; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01103; ADRENERGICR.
DR   PRINTS; PR00562; ADRENRGCB2AR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; Endosome;
KW   G-protein coupled receptor; Glycoprotein; Golgi apparatus; Hydroxylation;
KW   Lipoprotein; Membrane; Palmitate; Phosphoprotein; Receptor;
KW   Reference proteome; Transducer; Transmembrane; Transmembrane helix;
KW   Ubl conjugation.
FT   CHAIN           1..413
FT                   /note="Beta-2 adrenergic receptor"
FT                   /id="PRO_0000069130"
FT   TOPO_DOM        1..34
FT                   /note="Extracellular"
FT   TRANSMEM        35..58
FT                   /note="Helical; Name=1"
FT   TOPO_DOM        59..71
FT                   /note="Cytoplasmic"
FT   TRANSMEM        72..95
FT                   /note="Helical; Name=2"
FT   TOPO_DOM        96..106
FT                   /note="Extracellular"
FT   TRANSMEM        107..129
FT                   /note="Helical; Name=3"
FT   TOPO_DOM        130..150
FT                   /note="Cytoplasmic"
FT   TRANSMEM        151..174
FT                   /note="Helical; Name=4"
FT   TOPO_DOM        175..196
FT                   /note="Extracellular"
FT   TRANSMEM        197..220
FT                   /note="Helical; Name=5"
FT   TOPO_DOM        221..274
FT                   /note="Cytoplasmic"
FT   TRANSMEM        275..298
FT                   /note="Helical; Name=6"
FT   TOPO_DOM        299..305
FT                   /note="Extracellular"
FT   TRANSMEM        306..329
FT                   /note="Helical; Name=7"
FT   TOPO_DOM        330..413
FT                   /note="Cytoplasmic"
FT   REGION          193..207
FT                   /note="Agonist and antagonist binding"
FT   REGION          286..293
FT                   /note="Agonist and antagonist binding"
FT   REGION          312..316
FT                   /note="Agonist and antagonist binding"
FT   MOTIF           410..413
FT                   /note="PDZ-binding"
FT   BINDING         113
FT                   /note="Agonist or antagonist"
FT   BINDING         118
FT                   /note="Agonist or antagonist"
FT   MOD_RES         141
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:8521811"
FT   MOD_RES         246
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17525332"
FT   MOD_RES         261
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         262
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         345
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:11146000"
FT   MOD_RES         346
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:11146000"
FT   MOD_RES         355
FT                   /note="Phosphoserine; by BARK"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         356
FT                   /note="Phosphoserine; by BARK"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         382
FT                   /note="4-hydroxyproline"
FT                   /evidence="ECO:0000269|PubMed:19584355"
FT   MOD_RES         395
FT                   /note="4-hydroxyproline"
FT                   /evidence="ECO:0000269|PubMed:19584355"
FT   LIPID           265
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:27481942"
FT   LIPID           341
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:17962520,
FT                   ECO:0000269|PubMed:18547522, ECO:0000269|PubMed:2540197,
FT                   ECO:0000269|PubMed:27481942"
FT   CARBOHYD        6
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000305"
FT   CARBOHYD        15
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000305"
FT   DISULFID        106..191
FT   DISULFID        184..190
FT   VARIANT         15
FT                   /note="N -> S (in dbSNP:rs33973603)"
FT                   /id="VAR_049373"
FT   VARIANT         16
FT                   /note="G -> R (in dbSNP:rs1042713)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:3025863, ECO:0000269|PubMed:3033609,
FT                   ECO:0000269|PubMed:3034889, ECO:0000269|PubMed:7706471,
FT                   ECO:0000269|PubMed:7915137, ECO:0000269|PubMed:8383511,
FT                   ECO:0000269|Ref.8"
FT                   /id="VAR_003452"
FT   VARIANT         27
FT                   /note="E -> Q (in dbSNP:rs1042714)"
FT                   /evidence="ECO:0000269|PubMed:11246467,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:2823249,
FT                   ECO:0000269|PubMed:3025863, ECO:0000269|PubMed:3026848,
FT                   ECO:0000269|PubMed:3033609, ECO:0000269|PubMed:3034889,
FT                   ECO:0000269|PubMed:7915137, ECO:0000269|PubMed:8383511,
FT                   ECO:0000269|Ref.10, ECO:0000269|Ref.11, ECO:0000269|Ref.12,
FT                   ECO:0000269|Ref.8"
FT                   /id="VAR_003453"
FT   VARIANT         34
FT                   /note="V -> M (in dbSNP:rs990810566)"
FT                   /evidence="ECO:0000269|PubMed:8383511"
FT                   /id="VAR_003454"
FT   VARIANT         159
FT                   /note="I -> F"
FT                   /evidence="ECO:0000269|PubMed:11246467"
FT                   /id="VAR_009125"
FT   VARIANT         159
FT                   /note="I -> L"
FT                   /evidence="ECO:0000269|PubMed:11246467"
FT                   /id="VAR_009124"
FT   VARIANT         164
FT                   /note="T -> I (in dbSNP:rs1800888)"
FT                   /evidence="ECO:0000269|PubMed:8383511"
FT                   /id="VAR_003455"
FT   VARIANT         220
FT                   /note="S -> C (in dbSNP:rs3729943)"
FT                   /evidence="ECO:0000269|Ref.11"
FT                   /id="VAR_025101"
FT   VARIANT         375
FT                   /note="K -> R (in dbSNP:rs771585355)"
FT                   /evidence="ECO:0000269|PubMed:11246467"
FT                   /id="VAR_009394"
FT   MUTAGEN         79
FT                   /note="D->N: Affects binding of catecholamines, and
FT                   produces an uncoupling between the receptor and stimulatory
FT                   G proteins."
FT                   /evidence="ECO:0000269|PubMed:2831218"
FT   MUTAGEN         141
FT                   /note="Y->F: Abolishes insulin-induced tyrosine
FT                   phosphorylation and insulin-induced receptor
FT                   supersensitization."
FT                   /evidence="ECO:0000269|PubMed:8521811"
FT   MUTAGEN         265
FT                   /note="C->A: Loss of ligand-induced palmitoylation."
FT                   /evidence="ECO:0000269|PubMed:27481942"
FT   MUTAGEN         341
FT                   /note="C->A: Loss of basal palmitoylation."
FT                   /evidence="ECO:0000269|PubMed:27481942"
FT   MUTAGEN         341
FT                   /note="C->G: Uncoupled receptor."
FT                   /evidence="ECO:0000269|PubMed:2540197"
FT   MUTAGEN         345..346
FT                   /note="SS->AA: Delayed agonist-promoted desensitization."
FT                   /evidence="ECO:0000269|PubMed:11146000"
FT   MUTAGEN         350
FT                   /note="Y->A: Does not affect insulin-induced tyrosine
FT                   phosphorylation or insulin-induced receptor
FT                   supersensitization."
FT                   /evidence="ECO:0000269|PubMed:8521811"
FT   MUTAGEN         354
FT                   /note="Y->A: Does not affect insulin-induced tyrosine
FT                   phosphorylation or insulin-induced receptor
FT                   supersensitization."
FT                   /evidence="ECO:0000269|PubMed:8521811"
FT   MUTAGEN         366
FT                   /note="Y->F: Does not affect insulin-induced tyrosine
FT                   phosphorylation or insulin-induced receptor
FT                   supersensitization."
FT                   /evidence="ECO:0000269|PubMed:8521811"
FT   CONFLICT        71
FT                   /note="F -> L (in Ref. 9; BAG35969)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        216
FT                   /note="V -> A (in Ref. 8; AAN01267)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        261
FT                   /note="S -> P (in Ref. 10; BAD96745)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        402
FT                   /note="Q -> P (in Ref. 14; AAH12481)"
FT                   /evidence="ECO:0000305"
FT   STRAND          25..27
FT                   /evidence="ECO:0007744|PDB:3P0G"
FT   HELIX           31..60
FT                   /evidence="ECO:0007744|PDB:2RH1"
FT   HELIX           62..64
FT                   /evidence="ECO:0007744|PDB:2RH1"
FT   HELIX           67..85
FT                   /evidence="ECO:0007744|PDB:2RH1"
FT   HELIX           87..96
FT                   /evidence="ECO:0007744|PDB:2RH1"
FT   HELIX           102..136
FT                   /evidence="ECO:0007744|PDB:2RH1"
FT   STRAND          137..139
FT                   /evidence="ECO:0007744|PDB:2RH1"
FT   STRAND          140..142
FT                   /evidence="ECO:0007744|PDB:6PS2"
FT   HELIX           147..170
FT                   /evidence="ECO:0007744|PDB:2RH1"
FT   TURN            171..174
FT                   /evidence="ECO:0007744|PDB:2RH1"
FT   HELIX           179..186
FT                   /evidence="ECO:0007744|PDB:2RH1"
FT   STRAND          187..189
FT                   /evidence="ECO:0007744|PDB:3SN6"
FT   HELIX           197..207
FT                   /evidence="ECO:0007744|PDB:2RH1"
FT   HELIX           209..229
FT                   /evidence="ECO:0007744|PDB:2RH1"
FT   TURN            235..239
FT                   /evidence="ECO:0007744|PDB:2R4R"
FT   HELIX           267..298
FT                   /evidence="ECO:0007744|PDB:2RH1"
FT   STRAND          299..303
FT                   /evidence="ECO:0007744|PDB:6PS4"
FT   HELIX           305..317
FT                   /evidence="ECO:0007744|PDB:2RH1"
FT   HELIX           318..320
FT                   /evidence="ECO:0007744|PDB:2RH1"
FT   HELIX           322..325
FT                   /evidence="ECO:0007744|PDB:2RH1"
FT   HELIX           326..328
FT                   /evidence="ECO:0007744|PDB:2RH1"
FT   HELIX           330..339
FT                   /evidence="ECO:0007744|PDB:2RH1"
FT   TURN            340..342
FT                   /evidence="ECO:0007744|PDB:5JQH"
FT   TURN            345..347
FT                   /evidence="ECO:0007744|PDB:2R4R"
SQ   SEQUENCE   413 AA;  46459 MW;  408C22731C6EDFBE CRC64;
     MGQPGNGSAF LLAPNGSHAP DHDVTQERDE VWVVGMGIVM SLIVLAIVFG NVLVITAIAK
     FERLQTVTNY FITSLACADL VMGLAVVPFG AAHILMKMWT FGNFWCEFWT SIDVLCVTAS
     IETLCVIAVD RYFAITSPFK YQSLLTKNKA RVIILMVWIV SGLTSFLPIQ MHWYRATHQE
     AINCYANETC CDFFTNQAYA IASSIVSFYV PLVIMVFVYS RVFQEAKRQL QKIDKSEGRF
     HVQNLSQVEQ DGRTGHGLRR SSKFCLKEHK ALKTLGIIMG TFTLCWLPFF IVNIVHVIQD
     NLIRKEVYIL LNWIGYVNSG FNPLIYCRSP DFRIAFQELL CLRRSSLKAY GNGYSSNGNT
     GEQSGYHVEQ EKENKLLCED LPGTEDFVGH QGTVPSDNID SQGRNCSTND SLL
//
